Who
Henry O. Gosebruch
Director
Company insider
Files Form 4 as: Director, ANI Pharmaceuticals; Director, Acelyrin; President & CEO, Neumora Therapeutics; Director, Aptinyx; EVP, Chief Strategy Officer, AbbVie.
In numbers
- Trades disclosed
- 129
- Buys
- 6
- Sells
- 10
- Bought
- $3.6M
- Sold
- $46.4M
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 9 Dec 2015
- Last trade
- 19 Aug 2026
- Last filed
- 27 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Aug 2026filed 27 Aug 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —6,662 at $0.00 | filing |
| 19 Aug 2026filed 27 Aug 2026 | ANIP ANI PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —6,662 at $0.00 | filing |
| 21 May 2025filed 23 May 2025 | Acelyrinoption or derivative | SEC FORM 4 Code D | —92,158 | filing |
| 21 May 2025filed 23 May 2025 | Acelyrinoption or derivative | SEC FORM 4 Code D | —155,450 | filing |
| 21 May 2025filed 23 May 2025 | Acelyrin | SEC FORM 4 Code D | —50,000 | filing |
| 7 Jun 2024filed 11 Jun 2024 | Acelyrinoption or derivative | SEC FORM 4 Code A | —92,158 at $0.00 | filing |
| 14 Feb 2024filed 16 Feb 2024 | NMRA Neumora Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —160,000 at $0.00 | filing |
| 14 Feb 2024filed 16 Feb 2024 | NMRA Neumora TherapeuticsBiotechnology | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 19 Sep 2023filed 19 Sep 2023 | NMRA Neumora TherapeuticsBiotechnology | SEC FORM 4 Bought | $189K15,000 at $12.62 | filing |
| 9 May 2023filed 11 May 2023 | Acelyrinoption or derivative | SEC FORM 4 Code J | —155,450 at $0.00 | filing |
| 9 May 2023filed 11 May 2023 | Acelyrinoption or derivative | SEC FORM 4 Code J | —155,450 at $0.00 | filing |
| 9 May 2023filed 11 May 2023 | Acelyrin | SEC FORM 4 Bought | $900K50,000 at $18.00 | filing |
| 26 May 2022filed 31 May 2022 | Aptinyxoption or derivative | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 16 May 2022filed 20 May 2022 | ABBV AbbVieoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | $4.6M83,960 at $54.86 | filing |
| 16 May 2022filed 20 May 2022 | ABBV AbbViePharmaceuticals | SEC FORM 4 Code M | $4.6M83,960 at $54.86 | filing |
| 16 May 2022filed 20 May 2022 | ABBV AbbViePharmaceuticals | SEC FORM 4 Sold | $13.0M83,960 at $155.00 | filing |
| 16 May 2022filed 18 May 2022 | ABBV AbbVieoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | $4.6M83,960 at $54.86 | filing |
| 16 May 2022filed 18 May 2022 | ABBV AbbViePharmaceuticals | SEC FORM 4 Code M | $4.6M83,960 at $54.86 | filing |
| 16 May 2022filed 18 May 2022 | ABBV AbbViePharmaceuticals | SEC FORM 4 Sold | $13.0M83,960 at $155.00 | filing |
| 1 Mar 2022filed 20 May 2022 | ABBV AbbViePharmaceuticals | SEC FORM 4 Sold | $2.3M15,733 at $146.81 | filing |
News
AbbVie vs. Bristol Myers: Is AbbVie's Valuation Premium Worth Paying?ABBV · insidermonkey.com · 19 Oct 2026AbbVie: SKYRIZI (risankizumab) and RINVOQ (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026ABBV · finanznachrichten.de · 17 Oct 2026Pfizer vs. AbbVie: Is the Cheaper Pharma Stock Really the Better Investment?ABBV · insidermonkey.com · 16 Oct 2026
0 headlines in the last 90 days name Henry O. Gosebruch; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.